ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Prevention of Ischemia Reperfusion Injury (IRI) & ABMR in HLA Sensitized Patients Treated with C1 Esterase Inhibitor (C1INH): Long-Term Follow Up

A. A. Vo, E. Huang, N. Ammerman, J. Choi, I. Kim, A. Peng, R. Najjar, S. Sethi, K. Lim, S. C. Jordan

Cedars Sinai Medical Ctr, Los Angeles, CA

Meeting: 2019 American Transplant Congress

Abstract number: 111

Keywords: Glomerular filtration rate (GFR), Highly-sensitized, Ischemia, Kidney transplantation

Session Information

Date: Sunday, June 2, 2019

Session Name: Concurrent Session: Kidney Acute Antibody Mediated Rejection

Session Time: 4:30pm-6:00pm

 Presentation Time: 4:42pm-4:54pm

Location: Ballroom B

Related Abstracts
  • Ischemia Reperfusion Injury & Risk for Antibody Mediated Rejection (ABMR) in HLA Sensitized Patients Treated with C1 Esterase Inhibitor (C1INH)
  • C1 Esterase Inhibitor (C1INH) Treatment at Kidney Transplant Improves Long-Term Outcomes in Patients at Risk for Ischemia/Reperfusion Injury & Delayed Graft Function

*Purpose: Delayed graft function (DGF) after kidney transplantation is a consequence of IRI/DGF. IRI/DGF requires intense medical management, is costly and predisposes to risk for AR. Recent data show that complement activation may be an important mediator. In HLA sensitized (HS) patients, this can contribute to poor outcomes. We previously showed that patients who were randomized to receive C1INH (serine protease inhibitor that inhibits MBL/MASP) had earlier recovery from delayed graft than placebo. Here we report a post-hoc analysis on long-term outcomes in the subgroup of HS patients enrolled in the prior randomized placebo-controlled study.

*Methods: From November 2014 – February 2017, 70 patients at risk for IRI/DGF were enrolled and randomized 1:1 to receive C1INH 50U/kg (n=35) vs. placebo (n=35) intra-operatively & 24hrs later. Of the 70 patients, 17 were HLA sensitized. All transplanted HS patients received antibody induction with alemtuzumab and were maintained on standard immunosuppression with tacrolimus, cellcept, and tapering prednisone. Rejection episodes, patient and graft survival, and eGFR up to 48M were compared between recipients of C1INH and placebo.

*Results: Ten patients received C1INH and 7 received placebo. Briefly, cPRA 99-100% & previous transplants were similar between the 2 groups. All patients were off dialysis by day 15 and no significant differences were seen with time to dialysis cessation between C1INH and placebo. No ABMR was seen in C1INH treated patients vs. 2 patients (29%) in placebo. CMR was seen in 2 patients (20%) in C1INH vs. 1 patient (14%) in placebo. There were no graft losses among C1INH patients vs. 2 graft losses in placebo (p=0.07) {Fig 1}. One death occurred in the C1INH group @ 41M post-transplant d/t sepsis. A linear mixed effects model observed progressive deterioration in eGFR up to 48M in the placebo group (slope eGFR: -10.0 ml/min/1.73 m2, 95% CI: -18.5 to -1.48), whereas eGFR was stable among C1INH-treated recipients (slope eGFR: -0.08 ml/min/1.73 m2 per year; 95% CI: -6.97 to 6.81) {Fig 2}.

*Conclusions: C1INH therapy was associated with sustained graft survival with no antibody rejection episodes. There was progressive deterioration in eGFR among placebo treated patients, suggesting that the addition of C1INH may lead to long-term preservation of graft function in HS patients receiving donor allografts at risk for IRI/DGF.

 border=

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Vo AA, Huang E, Ammerman N, Choi J, Kim I, Peng A, Najjar R, Sethi S, Lim K, Jordan SC. Prevention of Ischemia Reperfusion Injury (IRI) & ABMR in HLA Sensitized Patients Treated with C1 Esterase Inhibitor (C1INH): Long-Term Follow Up [abstract]. Am J Transplant. 2019; 19 (suppl 3). https://atcmeetingabstracts.com/abstract/prevention-of-ischemia-reperfusion-injury-iri-abmr-in-hla-sensitized-patients-treated-with-c1-esterase-inhibitor-c1inh-long-term-follow-up/. Accessed March 5, 2021.

« Back to 2019 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.